Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Action(s) taken or orders passed
Regulatory Filings
2026-06-03 English
Permanent revocation of closure directions for Company''s Dahej Site
Regulatory Filings
2026-06-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 88% confidence The document is a formal notice filed under SEBI Listing Obligations to inform the exchanges of upcoming analyst/institutional investor meetings. It does not present financial results, a presentation deck, or voting outcomes, nor is it an annual or interim report. It is a regulatory disclosure of schedule under Listing Regulations, fitting the general category of miscellaneous regulatory announcements. Thus, it should be classified as a Regulatory Filing (RNS).
2026-06-01 English
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure under SEBI LODR, notifying stock exchanges of upcoming analyst/institutional investor meetings. It does not contain financial statements or provide investor presentation materials; rather, it is a routine compliance announcement. This aligns with the 'Regulatory Filings' category as a general regulatory announcement.
2026-06-01 English
Please find enclosed herewith the Annual Secretarial Compliance Report for the Financial Year 2025-2026.
Regulatory Filings Classification · 87% confidence The document is an Annual Secretarial Compliance Report filed under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a certification/attestation by the Company Secretary and Practicing Company Secretary on statutory and regulatory compliance (not a full financial statement or governance charter). It does not present financial results or detailed investor presentation material. Under the “Certification Rule,” documents that are officer certifications or regulatory compliance attestations are classified as Regulatory Filings (RNS).
2026-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges (BSE and NSE) about the schedule of upcoming analyst and institutional investor meetings. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating a regulatory compliance announcement. The content is purely informational about meeting dates and venues, with no financial data, report content, or detailed analysis. The document length is short (2134 characters), and it does not contain any financial statements or detailed report material. It is not a report itself but an announcement related to investor relations activities. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.